Skip to main content

Welcome to The Auphians

Welcome, Auphians, this is your site.

This is a troll free place where we can share the Auphian ride to success, and endure in good company all the bumps along the way. I am structuring this as a semi public forum where a handful of like minded investors can post freely with out censorship. It will take me a while to set up and vet the public posters, so thanks in advance for your patience.

That said, I'm dedicating this blog to Vidpok, the guy who saw this was a good company when most of had never even heard of it.

Stay tuned, and I look forward to travelling with all of you.

Sincerely,

TC

Comments

  1. Hey TC,
    Looking forward to some good conversation here without the noise.

    Mr_Feynman (on ST)

    ReplyDelete
  2. Hi Walkos on ST

    ReplyDelete
  3. Hey - farmecologist here. Followed you guys all the way through the ARIA ride...but didn't really post much. Appreciate the effort to set this bog up!

    ReplyDelete
  4. You guys following the price movement today? Thoughts?

    ReplyDelete
  5. what I posted on Ihub which was removed :

    Big guys playing with this :

    The savvy long-term investors never chase stocks up. For the most part that is momentum players and daytraders where most of it or what follows is dumb money. Instead the long-term investors use a couple of simple strategies in order to position themselves. One is to find a stock no one immediately sees has huge potential and accumulate. Long-term investors are not interested in trading against the public mind or the dumb money. That's where the majority of the money can be made but even more can be made if the base of a stock is held extremely strong by investors. However the second is not to doubt the research which is the underlying basis for going long and holding.



    More and more investors are winning the game nowadays despite all bashers [color=red][/color]that float through the Internet that has become part of the game. Some bashers appear to be bashing one day and the next praise the stock in order not to sound too negative. Floor traders of market makers often watch CNBC, news wires and bulletin boards in order to follow the market during trading session. OTC BB market makers (MMs) don't use fundamental and technical analysis. However, what they do realize is a lot of dumb money does use this newest nitch charting or TA (Technical Analysis) to run a stock either up or down. To the MMs this is like taking candy from a baby. Simply they will paint the tape and use whatever tactic to affect the charting bands. Thus the public and dumb money they will have eating out of their hands. Effectively the MMs can show a strong stock growing weak by manipulating the close price in order to generate selling volume, delaying trading time to manipulate trading activities, or even stalling the ask without honoring orders to hold a stock price.

    ReplyDelete
    Replies
    1. Thanks for your post, and very odd it was deleted from iHub. What's up with those guys???

      Delete
    2. I think I'm setting a record over there for deleted posts. The mods have it out for me. ;)

      Delete
    3. The mods on Ihub cannot help themselves. Tbey dont make the Ihub fascist rules but their very small monkey brains are only capable of following orders.

      Delete

Post a Comment

Popular posts from this blog

June 6, 2017. Buy Out at 63?

Take a spin on our BO pricing model! The Trading Cyclist Our model is generating a range of $35-63 BO PPS , per the low/high case scenarios below - where only the Voc  price  is different (25 k vs 50k). My hunch is that this is both conservative and in the ballpark.  It's conservative b/c: 1) patient population is consistent with Aurinia's projection; 2) assumes only 35% of population on treatment; 3) assumes 75% discount for European market; 4) pricing is at 50% of range projected by Aurinia; 5) uses target P/S ratio of 3, which is below Biotech industry average of 5.0.  Outcome   Patient Pool  (Same for both Scenarios)  Pricing :  Price/Sales ratio   Here's the  Link to the model Low end BO PPS w/30% discount:  $35  ($50 no discount)  High End BO PPS w/30% discount  $63  ($90 no discount)  Prev: 26.5 per 100,000 (Based on epidemiological study)  Total Patient pool (US, Europe, Japan): 252,333  % of patients on treatment: 50%  To

June 8, 2017: The case for early approval of Voclosporin

Voclosporin will likely be approved well before the P3 trial runs it course. Here's how it's going to work.  First, there's a legal and regulatory path for this approval .  While I quote the relevant passage below, here's the link to the  FDA Regulations , as well as  a   list of drugs   t hat received accelerated approval.  Sec. 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoin t that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant stud

iHub has been hijacked by trolls

Yup. iHub can't get rid of "Biotech Researcher," aka BR.  It's both a win for BR (the troll), and a huge loss for iHub. Their platform loses value and credibility when they refuse to take action on perma-trolls that derail the discussion and distract investors from their efforts to just honestly share information and opinions on the equities they own. So shame on iHub for not taking action to resolve this. I'm going to cease and desist on posting there until the troll (BR) problem has been resolved, and credible, valuable posters have been reinstated. I've already cancelled my premium membership some time ago. I suggest you do the same. With kind regards to all Trading Cyclist (aka TC)